Fas antigen derivatives
AssigneesMochida Pharmaceutical Co., Ltd., Osaka Bioscience Institute
InventorsNorio Nakamura, Shigekazu Nagata
Life of this patent
Estimating the term…
Loading patent…
AssigneesMochida Pharmaceutical Co., Ltd., Osaka Bioscience Institute
InventorsNorio Nakamura, Shigekazu Nagata
Estimating the term…
This invention provides a novel Fas antigen derivative which comprises at least a part or entire portion of Fas antigen extracellular region polypeptide in which at least one amino acid residue is deleted from a group of amino acid residues starting from the N-terminal amino acid residue of the Fas antigen polypeptide to a cysteine residue most close to the N-terminal side (excluding said cysteine residue), as well as a DNA fragment which encodes Fas antigen derivative, a recombinant DNA molecule which contains DNA sequence, a transformant in which recombinant DNA molecule is introduced, a method for the production of Fas antigen derivative, a medicament which contains novel Fas antigen derivative as the active ingredient and a method for the improvement of activities and functions of Fas antigen and the like.
A polypeptide comprising at least Fas antigen extracellular region polypeptide in which at least one amino acid residue is deleted from the 1st to 42nd amino acid residues counting from the N-terminus of SEQ ID NO:
Dependencies are inferred from the claim text.